Moderna posts Q1 2024 revenues at US$167 million

GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)

FDA grants full approval for TIVDAK to treat cervical cancer

TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer

Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion

First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data

The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg

Lilly posts Q1 2024 revenue up 26% at US$ 8.77 billion

2024 full-year revenue guidance raised by US$ 2 billion

Granules India announced ANDA Approval for Colchicine Capsules

Colchicine Capsules are indicated for prophylaxis of gout flares in adult

Lonza launches AI-enabled Route Scouting Service to accelerate small molecule development

New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)

Gland Pharma receives approval for cetrorelix acetate for injection

AstraZeneca’s Truqap plus Faslodex recommended for approval in the EU by CHMP for cancer treatment

Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%

Glenmark receives ANDA approval for acetaminophen and ibuprofen tablets

Glenmark’s Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), will be distributed in the U.S. by Glenmark Therapeutics, USA